MedTrace Logo

Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment

NCT02084420 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 323

Last updated 2014-06-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate of efficacy and safety as H.pylori eradiation effect between Ilaprazole and Pantoprazole triple therapy for 7 days treatment in Gastric and/or Duodenal ulcer patients with H.pylori positive infection.

Conditions

  • Peptic Ulcer

Interventions

DRUG

Ilaprazole

10mg 2 BID( 2 times / day), before breakfast and dinner

DRUG

Pantoprazole

40mg, BID(2 times / day), before breakfast and dinner

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • IL YANG PHARM · IL-YANG Pharmaceutical Co.LTD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084420 on ClinicalTrials.gov